natgillin/translations-raw huggingface dataset:
What Telmisartan Teva looks like and contents of the pack
Izgled zdravila Telmisartan Teva in vsebina pakiranja
The other side of the tablet is debossed with the number "7459".
Na eni strani tablete je odtisnjena številka "93", na drugi strani tablete pa številka "7459".
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
Endpoints) je preučevala koristi dodatka aliskirena standardnemu zdravljenju z zaviralcem ACE ali blokatorjem receptorjev angiotenzina II pri bolnikih s sladkorno boleznijo tipa 2 in kronično boleznijo ledvic, kardiovaskularno boleznijo ali obojim.
As observed for angiotensin converting enzyme inhibitors, telmisartan and the other angiotensin II receptor antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population.
Kot je bilo ugotovljeno za zaviralce angiotenzinske konvertaze, tudi telmisartan in drugi antagonisti receptorjev angiotenzina II manj učinkovito znižujejo krvni tlak pri črni rasi v primerjavi z drugimi rasami.
Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.
Ti izsledki so pomembni tudi za druge zaviralce ACE in blokatorje receptorjev angiotenzina
Exposure to angiotensin II receptor antagonist therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia).
Znano je, da izpostavljenost antagonistom angiotenzina II v drugem in tretjem trimesečju nosečnosti lahko povzroči fetotoksične učinke pri človeku (zmanjšano delovanje ledvic, oligohidramnij, zapoznela zakostenitev lobanje) in toksične učinke pri novorojenčku (ledvična odpoved, hipotenzija, hiperkaliemija)
The use of angiotensin II receptor antagonists is not recommended during the first trimester of pregnancy (see section 4.4).
Uporaba antagonistov angiotenzina II v prvem trimesečju nosečnosti ni priporočljiva (glejte poglavje 4.4.).
Telmisartan Teva should be used only with caution in patients with mild to moderate hepatic impairment.
Zdravilo Telmisartan Teva moramo previdno dajati bolnikom z zmerno hudo do hudo jetrno okvaro.
Carefully peel off the top paper layer
Previdno odstranite vrhnjo papirno plast omota.
Blood creatinine increased
zvišana raven kreatinina
Alternatively, Telmisartan Teva may be used in combination with diuretics (“water” tablets) such as hydrochlorothiazide which has been shown to have an additive blood pressure lowering effect with Telmisartan Teva.
Telmisartan se lahko uporablja tudi v kombinaciji z diuretiki (tablete za odvajanje vode), kot je hidroklorotiazid, ki v kombinaciji s telmisartanom dodatno zniža krvni tlak.
ONTARGET (ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) compared the effects of telmisartan, ramipril and the combination of telmisartan and ramipril on cardiovascular outcomes in 25620 patients aged 55 years or older with a history of coronary artery disease, stroke, TIA, peripheral arterial disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage (e.g. retinopathy, left ventricular hypertrophy, macro- or microalbuminuria), which is a population at risk for cardiovascular events.
V študiji ONTARGET (ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) so primerjali učinke telmisartana, ramiprila in kombinacije telmisartana in ramiprila na srčnožilne izide pri 25.620 bolnikih, starih 55 let ali starejših, ki so imeli v anamnezi koronarno arterijsko bolezen,
The safety profile of telmisartan in patients treated for the reduction of cardiovascular morbidity was consistent with that obtained in hypertensive patients.
Varnostni profil telmisartana je bil pri bolnikih, ki so zdravilo jemali za zmanjševanje pojavnosti srčnožilnih bolezni enak kot pri bolnikih s hipertenzijo.
Angioedema (also with fatal outcome), eczema, erythema, urticaria, drug eruption, toxic skin eruption
angioedem (tudi z usodnim izidom), ekcem, eritem,
There is no linear relationship between doses and plasma levels.
Razmerje med odmerki in plazemskimi koncentracijami ni linearno.
These patients can be expected to have reduced hepatic clearance for telmisartan.
Pri bolnikih z naštetimi obolenji je lahko zmanjšan jetrni očistek telmisartana.
The other side of the tablet is debossed with the number "7460".
Na eni strani tablete je odtisnjena številka "93", na drugi strani tablete pa številka "7460".
However, your doctor may recommend a lower dose of 20 mg or a higher dose of 80 mg. Alternatively, Telmisartan Teva may be used in combination with diuretics (“water” tablets) such as hydrochlorothiazide which has been shown to have an additive blood pressure lowering effect with Telmisartan Teva.
Kadar s priporočenim odmerkom ne dosežemo želenega znižanja krvnega tlaka, lahko odmerek telmisartana povečamo do največ 80 mg enkrat na dan. Telmisartan lahko uporabljamo tudi v kombinaciji s tiazidnimi diuretiki, kot je npr. hidroklorotiazid, za katerega se je pokazalo, da ima v kombinaciji s telmisartanom aditivni učinek na znižanje krvnega tlaka.
No pharmacological activity has been shown for the conjugate.
Konjugat ni farmakološko aktiven.
Uncommon side effects (may affect up to 1 in 100 people):
Občasni neželeni učinki(pojavijo se lahko pri največ 1 od 100 bolnikov):
14x1 tablets 28x1 tablets 30x1 tablets 40x1 tablets 56x1 tablets 60x1 tablets 84x1 tablets 90x1 tablets 98x1 tablets 100x1 tablets 30 tablets
14x1 tableta 28x1 tableta 30x1 tableta 40x1 tableta 56x1 tableta 60x1 tableta 84x1 tableta 90x1 tableta 98x1 tableta 100x1 tableta 30 tablet
Increase in certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), severe allergic reaction (anaphylactic reaction), allergic reaction (e.g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), low blood sugar levels (in diabetic patients), feeling anxious, somnolence, impaired vision, fast heart beat (tachycardia), dry mouth, upset stomach, taste disturbance (dysgeusia), abnormal liver function (Japanese patients are more likely to experience these side effects), eczema (a skin disorder), redness of skin, hives (urticaria), severe drug rash, joint pain (arthralgia), pain in extremity, tendon pain, flu-like-illness, decreased haemoglobin (a blood protein), increased levels of uric acid, increased hepatic enzymes or creatine phosphokinase in the blood.
piskanje, otekanje obraza ali nizek krvni tlak), nizka raven krvnega sladkorja (pri bolnikih s sladkorno boleznijo), občutek tesnobe, zaspanost, motnje vida, hitro bitje srca (tahikardija), suha usta, želodčne težave, motnje okusa (disgevzija), motnje v delovanju jeter (pri japonskih bolnikih obstaja večja verjetnost pojavljanja teh neželenih učinkov), ekcem (kožno obolenje), kožna rdečica, izpuščaji (utikarija), hud medikamentni izpuščaj, bolečina v sklepih (artralgija), bolečina v okončini, bolečina v kitah, gripi podobna bolezen, znižan hemoglobin (krvna beljakovina), zvišana raven sečne kisline, zvišana raven jetrnih encimov ali kreatin fosfokinaze v krvi.
• Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain ‘water tablets'), ACE inhibitors, angiotensin II receptor antagonists, NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen), heparin, immunosuppressives (e.g. cyclosporin or tacrolimus), and the antibiotic trimethoprim.
• Zdravila, ki lahko povečajo raven kalija v krvi, kot so nadomestki soli s kalijem, diuretiki, ki zadržujejo kalij (nekatere tablete za odvajanje vode), ACE zaviralci, antagonisti receptorjev angiotenzina II, nesteroidna protivnetna zdravila (NSAID, npr. acetilsalicilna kilsina, ibuprofen), heparin, imunosupresivi (npr. ciklosporin, takrolimus) in antibiotik trimetoprim.
Corticosteroïds (systemic route) Reduction of the antihypertensive effect.
Zmanjšajo antihipertenzivni učinek.
A), poloxamers, meglumine, povidone (PVP K-30), sorbitol (E420), magnesium stearate
Druge sestavine zdravila so mikrokristalina celuloza (Avicel PH 102), natrijev karboksimetilškrob (vrsta A), poloksameri, meglumin, povidon (PVP K-30), sorbitol (E420), magnezijev stearat.
In the PRoFESS trial, an increased incidence of sepsis was observed with telmisartan compared with placebo.
Evaluation Study), v kateri so proučevali učinek ramiprila v primerjavi s placebom.
Telmisartan Teva is provided in peelable perforated unit-dose aluminium-aluminium blisters and perforated unit-dose aluminium-aluminium blisters containing 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tablets for each type of blister presentation, although not all pack sizes may be marketed.
Zdravilo Telmisartan Teva je na voljo v aluminij-aluminij perforiranih enoodmernih pretisnih omotih z odstranljivo folijoin aluminij-aluminij perforiranih enoodmernih pretisnih omotih po 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tableta za vsako obliko pretisnega omota.
No posology adjustment is required for patients with mild to moderate renal impairment.
Bolnikom z blago do zmerno ledvično okvaro ni treba prilagajati odmerka.
The overall incidence of adverse reactions reported with telmisartan was usually comparable to placebo (41.4% vs 43.9 %) in controlled trials in patients treated for hypertension.
V s placebom nadzorovanih kliničnih preskušanjih pri bolnikih, ki so se zdravili zaradi hipertenzije, je bila skupna pogostnost neželenih dogodkov podobna pri telmisartanu in placebu (41,4 % v primerjavi s 43,9 %).
LIST OF EXCIPIENTS Contains sorbitol (E420).
Vsebuje sorbitol (E420).
Sepsis (often called "blood poisoning", is a severe infection with whole-body inflammatory response usually accompanied by high fevers, hot, flushed skin, elevated heart rate, rapid breathing, altered mental status, swelling, and low blood pressure), rapid swelling of the skin and mucosa (angioedema); these side effects are rare (may affect up to 1 in 1,000 people) but are extremely serious and patients should stop taking the medicine and see their doctor immediately.
Sepsa (pogosto poimenovana tudi zastrupitev krvi, je huda okužba, pri kateri pride v vsem telesu do vnetnega odziva, ki ga običajno spremlja visoka vročina, vroča, pordela koža, povišan srčni utrip, hitro dihanje, spremenjeno duševno stanje, otekanje in nizek krvni tlak), hitro otekanje kože in sluznice
At the beginning of the preventive therapy with Telmisartan Teva 80 mg, blood pressure should be frequently monitored.
Za zmanjševanje srčnožilnih dogodkov je običajni odmerek zdravila Telmisartan Teva ena tableta po 80 mg na dan. Na začetku preventivnega zdravljenja z zdravilom Telmisartan Teva 80 mg je treba pogosto izmeriti krvni tlak.
Hepatic function abnormal / liver disorder
Nenormalno delovanje jeter/ jetrna bolezen
Some people feel dizzy or tired when taking Telmisartan Teva.
Občasno se lahko med zdravljenjem z zdravilom Telmisartan Teva pojavita omotica ali utrujenost.
However, lower plasma concentrations were observed in patients with renal insufficiency undergoing dialysis.
Kakorkoli, bolnikom z ledvično okvaro, ki so se zdravili z dializo, so izmerili manjše koncentracije v plazmi.
potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal antiinflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim.
zaviralci ACE, antagonisti receptorjev angiotenzina II, nesteroidna protivnetna zdravila (tudi selektivni zaviralci ciklooksigenaze 2), heparin, imunosupresivi (ciklosporin ali takrolimus) in trimetoprim).
The recommended dose is 80 mg once daily.
Obiačjno učinkovit odmerek je 40 mg enkrat na dan.
Medicinal products or therapeutic classes of medicinal products that may provoke hyperkalaemia are salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti-inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim.
Zdravila ali terapevtske skupine zdravil, ki lahko povzročijo hiperkaliemijo so nadomestki soli s kalijem, diuretiki, ki zadržujejo kalij, zaviralci ACE, antagonisti receptorjev angiotenzina II, nesteroidna protivnetna zdravila (tudi selektivni zaviralci ciklooksigenaze 2); heparin, imunosupresivi (ciklosporin ali takrolimus) in trimetoprim;
Microcrystalline cellulose (Avicel PH 102) Sodium starch glycolate (Type A) Poloxamers
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi mikrokristalna celuloza (Avicel PH 102) natrijev karboksimetilškrob (vrsta A) poloksameri meglumin povidon (PVP K-30) sorbitol (E420) magnezijev stearat
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton of peelable blisters
PODATKI NA ZUNANJI OVOJNINI Škatla za pretisne omote z odstranljivo folijo
Pack sizes of 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tablets for perforated blisters.
Pakiranja po 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tableta za perforirane enoodmerne pretisne omote.
Anxiety
anksioznost
In the “Prevention Regimen For Effectively avoiding Second Strokes” (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70 % vs. 0.49 % [RR 1.43 (95 % confidence interval 1.00 - 2.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33 %) vs. patients taking placebo (0.16 %) [RR 2.07 (95 % confidence interval 1.14 - 3.76)].
50 let in več, ki so nedavno preboleli kap, so opazili povečano incidenco sepse pri bolnikih s telmisartanom v primerjavi z bolniki s placebom (0,70 % v primerjavi z 0,49 % [RR 1,43 (95 % interval zaupanja 1,00 - 2,06)].
Pack sizes of 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tablets for peelable perforated blisters.
Pakiranja po 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tableta za perforirane enoodmerne pretisne omote z odstranljivo folijo.
Therefore it is not expected to potentiate bradykininmediated adverse effects.
encima, ki tudi razgrajuje bradikinin, zato predvidoma ne poveča neželenih učinkov, katere povzroča bradikinin.
Interstinal lung disease4
intersticijska pljučna bolezen4
Telmisartan displaces angiotensin II with very high affinity from its binding site at the AT1 receptor subtype, which is responsible for the known actions of angiotensin II.
Z veliko afiniteto spodriva angiotenzin II z njegovega vezavnega mesta na podtipu receptorja
Meglumine
bruhanje
Telmisartan Teva is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.
Če boste želeli dojiti, bo zdravnik za vas izbral drugo zdravilo, še zlasti, če je vaš otrok novorojenček ali nedonošenček.
Telmisartan Teva 20 mg Tablets Telmisartan
Telmisartan Teva 20 mg tablete telmisartan
These changes, also a class effect of angiotensin converting enzyme inhibitors and other angiotensin II receptor antagonists, do not appear to have clinical significance.
Kaže, da te spremembe, ki so skupna značilnost celotne skupine zdravil, kamor sodijo zaviralci angiotenzinske konvertaze in drugi antagonisti receptorjev angiotenzina II,
Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).
(RAAS) s hkratno uporabo zaviralcev ACE, blokatorjev receptorjev angiotenzina II ali aliskirena povezana z večjo pogostnostjo neželenih učinkov, npr. hipotenzije, hiperkaliemije in zmanjšanega delovanja ledvic (vključno z akutno odpovedjo ledvic) kot uporaba enega samega zdravila, ki deluje na RAAS (glejte poglavja 4.3, 4.4. in 5.1).
Patients with renal impairment
Posebne populacije Bolniki z ledvično okvaro
Prior treatment with high dose diuretics such as furosemide (loop diuretic) and hydrochlorothiazide (thiazide diuretic) may result in volume depletion, and in a risk of hypotension when initiating therapy with telmisartan.
Diuretiki (tiazidni diuretiki ali diuretiki Henlejeve zanke) Ob uvedbi telmisartana sta možni posledici predhodnega zdravljenja z visokimi odmerki diuretikov, kot sta furosemid (diuretik zanke) in hidroklorotiazid (tiazidni diuretik), izguba zunajcelične tekočine in nevarnost hipotenzije.
Therefore, in these patients an approptiate blood glucose monitoring should be considered; a dose adjustment of insulin or antidiabetics may be required, when indicated.
Če za to obstaja indikacija, je včasih treba prilagoditi odmerek insulina ali peroralnega antidiabetika.
Urinary tract infections, upper respiratory tract infection (e.g. sore throat, inflamed sinuses, common cold), deficiency in red blood cells (anaemia), high potassium levels, difficulty falling asleep, feeling sad (depression), fainting (syncope), feeling of spinning (vertigo), slow heart rate (bradycardia), low blood pressure (hypotension) in users treated for high blood pressure, dizziness on standing up (orthostatic hypotension), shortness of breath, cough, abdominal pain, diarrhoea, discomfort in the abdomen, bloating, vomiting, itching, increased sweating, drug rash, back pain, muscle cramps, muscle pain (myalgia), kidney impairment including acute kidney failure, pain in the chest, feeling of weakness, and increased level of creatinine in the blood.
Okužbe sečil, okužbe zgornjih dihal (npr. vneto grlo, vnetje sinusov, prehlad), pomanjkanje rdečih krvnih celic (anemija), visoka raven kalija, težave z uspavanjem, občutek žalosti (depresija), omedlevica (sinkopa), občutek vrtenja (vrtoglavica), počasen srčni utrip (bradikardija), nizek krvni tlak (hipotenzija) pri osebah, ki se zdravijo zaradi visokega krvnega tlaka, omotica pri vstajanju (ortostatska hipotenzija),
Telmisartan Teva 80 mg Tablets Telmisartan
Telmisartan Teva 80 mg tablete telmisartan
The blood pressure lowering effect of telmisartan can be increased by concomitant use of other antihypertensive medicinal products.
Sočasno jemanje drugih antihipertenzivov lahko poveča telmisartanov antihiperetenzivni učinek.
There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system.
Ledvičnožilna hipertenzija Pri bolnikih z obojestransko zožitvijo ledvične arterije ali zožitvijo arterije samo ene delujoče ledvice zdravljenje z zdravili, ki delujejo na renin-angiotenzin-aldosteronski sistem, poveča nevarnost hude hipotenzije in zmanjšanja delovanja ledvic.
Each tablet contains 85.6 mg sorbitol (E420) For the full list of excipients, see section 6.1.
Ena tableta vsebuje 85,6 mg sorbitola (E420).
- This medicine has been prescribed for you only.
Izdaja zdravila je le na recept.
There is no experience regarding the administration of Telmisartan Teva in patients with recent kidney transplantation.
Pri bolnikih z nedavno presajeno ledvico ni izkušenj z uporabo zdravila Telmisartan Teva.
Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors, and with angiotensin II receptor antagonists, including telmisartan.
Med sočasnim dajanjem litija in zaviralcev angiotenzin-konvertaze ter antagonistov receptorjev angiotenzina II, vključno s telmisartanom, so poročali o reverzibilnem povečanju ravni litija v serumu in toksičnih pojavih.
Somnolence
somnolenca
There was no evidence for benefit on cardiovascular mortality (hazard ratio 1.03, 95 % CI 0.85 - 1.24).
= 0,048)], medtem ko korist pri srčnožilni umrljivosti ni bila dokazana (razmerje tveganja 1,03, 95
Always take Telmisartan Teva exactly as your doctor has told you.
Pri jemanju zdravila Telmisartan Teva natančno upoštevajte navodila¸zdravnika.
• Severe hepatic impairment
• obolenja z zaporo žolčevoda • huda jetrna okvara
Do not pass it on to others.
Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
There is an apparent trend to a dose relationship to a time to recovery of baseline systolic blood pressure (SBP).
Rezultati raziskav kažejo na nakazano povezanost med odmerkom in časom, v katerem se povrnejo začetne vrednosti sistoličnega krvnega tlaka.
Symptomatic hypotension, especially after the first dose of Telmisartan Teva, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea, or vomiting.
Pri bolnikih z zmanjšanim volumnom krvi in/ali zmanjšano količino natrija zaradi intenzivnega diuretičnega zdravljenja, omejitve količine soli v hrani, driske ali bruhanja, se zlasti po prvem odmerku zdravila Telmisartan Teva lahko pojavi simptomatska hipotenzija.
Each tablet contains 21.4 mg sorbitol (E420) For the full list of excipients, see section 6.1.
Ena tableta vsebuje 21,4 mg sorbitola (E420).
If you get any side effects,talk to your doctor or pharmacist.
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom ali farmacevtom.
• if you are taking any of the following medicines used to treat high blood pressure: - an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetesrelated kidney problems.
- zaviralec ACE (na primer enalapril, lizinopril ali ramipril), zlasti če imate kakšne težave z ledvicami, ki so povezane s sladkorno boleznijo, - aliskiren.
Most cases of hepatic function abnormal / liver disorder from post-marketing experience occurred in Japanese patients.
O večini primerov nenormalnega delovanja jeter ali jetrne bolezni so v obdobju po začetku trženja telmisartana poročali pri japonskih bolnikih, pri katerih tudi sicer obstaja večja verjetnost teh neželenih reakcij.
Telmisartan does not inhibit angiotensin converting enzyme (kininase II), the enzyme which also degrades bradykinin.
Ne zavira angiotenzinske konvertaze (kinaze II)
Unless continued angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.
Pri bolnicah, ki načrtujejo nosečnost, je treba čim prej preiti na alternativno hipertenzivno zdravljenje z uveljavljenim varnostnim profilom za uporabo v nosečnosti; razen če se oceni, da je nadaljnje zdravljenje z antagonisti angiotenzina II nujno.
Each Telmisartan Teva tablet contains 40 mg telmisartan.
Ena tableta vsebuje 40 mg telmisartana.
NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 40 mg tablets telmisartan
Navodilo za uporabo Telmisartan Teva 40 mg tablete telmisartan
NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 80 mg tablets telmisartan
Navodilo za uporabo Telmisartan Teva 80 mg tablete telmisartan
Each Telmisartan Teva tablet contains 80 mg telmisartan.
Ena tableta vsebuje 80 mg telmisartana.
Each Telmisartan Teva tablet contains 20 mg telmisartan.
Ena tableta vsebuje 20 mg telmisartana.